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Abstract 
Notwithstanding the high rates of pertussis infant 
vaccination coverage in developed countries, 
Bortedella pertussis infections are manifesting a 
changing epidemiological pattern of disease. Of 
notable concern is the rise of pertussis in adolescents 
and adults. This changing picture is largely attributable 
to waning immunity after natural infection or 
vaccination. The belief that pertussis is chiefly a 
childhood disease is a common misconception. A 
significant rise of pertussis cases in Malta in older age 
groups was recorded in 2011. The addition of an 
adolescent and/or an adult booster dose against 
pertussis should be strongly considered. 
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Introduction 
Pertussis (whooping cough) is a highly contagious, 
acute infection caused by the gram-negative bacterium 
Bortedella pertussis. The classical clinical features of 
pertussis progress in stages and start with an irritating 
cough (catarrhal stage) which within 1-2 weeks 
becomes increasingly paroxysmal. The paroxysmal 
stage, which lasts for 2 weeks, is characterised by 
paroxysms of violent coughing that continue 
uninterrupted and may be followed by the 
characteristic inspiratory whoop and or post-tussive 
vomiting. After a period of violent paroxysms, the 
severity of the cough tapers off with an extensive 
convalescent period that may range between 2-6 weeks 
and in some cases may last up to 3 months
.1-2
 
Infants have the highest reported rates of illness.
3
 
However, pertussis may affect persons of all ages
4
 and 
is increasingly being reported in adolescents and adults 
in many European countries (e.g. Austria, France, 
Germany) and in the USA irrespective of vaccination 
status.
5-7
 Global incidence of pertussis (mostly in 
developing countries) has been estimated at 48.5 
million cases, with 295,000 deaths, per year.
8
 
Transmission of B. pertussis occurs from person 
to person via aerosol or by direct contact with infected 
respiratory secretions. Secondary attack rates in non-
immune households reach up to 90%.
2,8
 Even in 
countries where an effective childhood immunisation 
programme against pertussis is established, increasing 
rates of infection among adolescents and adults, as a 
result of waning of vaccine induced immunity, has 
been reported.
6,8,9
 In these cases, and in contrast to the 
pre-vaccine era, the manifestations are atypical, may 
be less severe and may lack the pathognomonic 
inspiratory whoop and/or post-tussive vomiting
10
 
(pertussis should be considered in the differential 
diagnosis of cough illness lasting more than 1-2wks).
11 
Furthermore, pertussis infections in adults and 
adolescents can often be asymptomatic.
12-13
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Pertussis complications in adolescents and adults 
include pneumonia, rib fractures, and 
encephalopathy.
10
 One study reported that 31% of 
adults suffering from acute exacerbations of chronic 
obstructive pulmonary disease (COPD) were also 
infected with B. pertussis.
14
 The socioeconomic 
burden can be significant: a French study found that 
half of 77 health-care workers with suspected pertussis 
missed 5 days of work accounting for 42% loss in 
productivity.
15
 
In spite of the high rates of vaccination coverage 
in developed countries, the changing epidemiological 
pattern of pertussis, in particular its rise in adolescents 
and adults is a cause of concern. The belief that 
pertussis is chiefly a childhood disease is a common 
misconception.
10
 On the contrary, it is infected 
adolescents and adults who pose a transmission risk to 
non-immune infants.
10
 In this study we investigated 
changes in the trends of pertussis in Malta by 
comparing reported cases of pertussis in 2011 with the 
previous decade.  
 
Methods  
As a statutory notifiable disease the collection of 
pertussis data in the Maltese islands were dependent 
on notifications from hospital and community based 
medical practitioners. Pertussis data in the Maltese 
population, from 2001 to 2011, were extracted from 
the national database of the Directorate for Health 
Promotion and Disease Prevention (IDCU). The 
European Centre for Disease Prevention and Control 
(ECDC) definition criteria for pertussis was used to 
subdivide cases into confirmed cases (clinical 
compatible cases with laboratory confirmation), 
probable cases (clinical compatible cases with an 
epidemiological link) and possible cases (cases with a 
clinical compatible nature only). Notified cases that 
did not confirm with the ECDC definition were 
excluded from the national data base and not included 
in the study.  
Chi-square test was used to analyse any 
differences between the notifications in 2011 and the 
previous decade while confidence intervals were 
calculated. All the yearly notified cases of pertussis in 
the previous decade of 2001-2010 were reviewed in 
the national database and reproduced for comparison 
(table 1). 
 
Results 
In 2011 an increase in the number of pertussis 
cases in Malta was reported (Figure 1). Four clusters 
consisting of three clusters of 2 cases each and one 
cluster of 5 cases making up a total of 11 cases (9 
laboratory confirmed, 2 epidemiologically linked) 
were reported. In addition 20 single notifications of 
pertussis were reported. Of the total number (n=31) of 
cases notified five cases were excluded from and 26 
were included in the disease register according to the 
ECDC’s definition.  
Serologically confirmed cases were those that 
registered significantly high pertussis toxin IgA and 
IgG as measured by ELISA. Bortedella pertussis 
culture or PCR were not performed because cases 
presented outside the necessary window period of two 
weeks post disease onset. (Tests were performed in 
Bioscientia Laboratories, Germany).   
There was a definite rise in the number of 
confirmed reported cases in 2011 (14 confirmed cases: 
four clusters with 9 confirmed cases; while 5 were 
confirmed sporadic cases) and 12 probable and 
possible cases (14+12: n=26) as compared to the 
reported cases over the previous ten years (Table 1), 
that is 2001-2010 (n=30, with an average notification 
of 3/year [95% confidence interval: 1.95-4.04]). This 
means a greater than eightfold significant rise (Chi-
square test with Yates correction 16.1, p<0.0001, 0.5% 
significance
16
) in 2011 over the average yearly figure 
of the previous decade. For the calculation the figure 
of the mid-year population of Malta for the year 2011 
was considered as the average population in that year 
(population 416,110), whereas the mid-year population 
in 2005 (population 404,962) was considered as the 
average Maltese population of the previous decade 
(2001-2010).
17
 
The average duration of symptoms at time of 
notification was 4.35 weeks while the range was 2-8 
weeks. Out of all the notified cases (and excluding the 
epidemiologically linked cases in the clusters) ten 
cases (mean age 20.1yrs; range 2-40yrs) claimed to 
have received a pertussis vaccine (full vaccination 
status could not be verified since the question on 
previous immunisation was too generic), three were 
not vaccinated (age range 44–85 yrs) while six cases 
(mean age 45 yrs; range 20-70yrs) did not know their 
vaccination status.  
All the cases presented between March and 
September with 69% (18/26) occurring in the three-
month period between March-May 2011. Case gender 
distribution was almost equal (14 M:12 F). 
In 2011 pertussis was more common in 
adolescents (age range: 10-14 years) and adults (age 
range 20-85). The reported cases in the previous 
decade (2001-2010) were mainly in children and to a 
lesser extent, in adolescents19 (Figure 1). 
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Table 1: Yearly notified pertussis cases during the period 2001-2010; *including 3 sporadic cases and two clusters of two 
persons each in 2005.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1: Comparison of the age distribution of the reported pertussis cases 2001-2010 & 2011 
 
The pertussis incidence rate (all cases) in Malta 
during 2011 was 6.32/100,000 population whereas the 
average incidence rate in EU/EEA countries was 
4.7/100,000 (range 0.2 (Cyprus) – 35.7/100,000 
(Estonia)).
20
 These contrasting figures are limited by 
differences in vaccination policies, case definitions, 
reporting procedures and surveillance systems. 
 
Discussion 
Notable differences in the age groups of the 
reported cases can be observed (Figure 1).  In 2011 
pertussis was commoner in adolescents and adults as 
compared to the reported cases in the previous decade 
where pertussis occurred predominantly in children. 
The reported incidence of pertussis is probably 
lower than the actual rates as under-reporting and 
under-recognition or mis-diagnosis in adolescents and 
adults are common.
5,10,21
 This is likely to be due to the 
altered clinical features of the disease in these age 
groups - as prolonged cough may be the only clinical 
feature present. Under-recognition may occur, some 
may present late while others may not present at all.
22
 
The limited local data, the possibility of an 
increased ascertainment of disease, a change in the 
diagnostic practice or a change in population 
characteristics and changes in disease susceptibility
10
 
all confound the recent rise in pertussis cases in Malta. 
In addition, although four-yearly epidemic trends of 
pertussis have been reported elsewhere,
2,11
 these have 
not been observed in Malta; the national database does 
not reflect the true epidemiological picture over the 
years as it relies solely on notification from medical 
practitioners. 
The Maltese National Immunisation Service 
(NIS) electronic database records National Health 
Service immunisation data as well as data of reported 
vaccinations from the private sector. The latter is 
marked by under-reporting and is thought to result in 
apparent lower national rates of vaccination as shown 
by the 3
rd
 dose uptake of pertussis vaccine in figure 2. 
In September 2010, the whole cell pertussis 
vaccine formulation recommended by the National 
Immunisation Schedule was changed to an acellular 
pertussis containing vaccine, with the first dose being 
administered at 6 weeks, the 2
nd
 at 3 months and the 3
rd
 
at 4 months of age. Combination vaccines containing 
acellular pertussis had been previously available on the 
private market for a number of years. A fourth 
acellular pertussis vaccine dose was also introduced on 
the National Immunisation Schedule in 2010 as part of 
a combination vaccine (Diphtheria, Tetanus, 
Inactivated Polio, Haemophilus Influenzae type b and 
acellular Pertussis vaccine) for 18 month old toddlers. 
This explains the higher 4
th
 dose vaccination 
notification rates from 2010 onwards, with the rates 
reported in previous years being from the private 
sector. 
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Pertussis vaccinations (3rd, 4th doses) compared to total live 
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Figure 2: Third & fourth dose pertussis vaccinations registered at NIS (National Immunisation Service) 1999-2011 
(NIS data) 
 
Despite high vaccination rates, B. pertussis 
infections have persisted as a consequence of waning 
vaccine-induced (lasting for 4-12 years) and naturally 
acquired immunity (lasting for 4-20 years).
23,10
 In the 
absence of further boosting, adolescents and adults 
(especially mothers) are likely to remain a reservoir of 
infection and play an important role in transmitting B. 
pertussis infection to incompletely immunised or 
unimmunised infants.
20,24
 
Current literature supports the addition of a single 
adolescent and/or an adult booster dose of pertussis 
vaccine.
25-27
 In some countries this is already being 
implemented
28-29 
following thorough country-specific 
evaluations of the epidemiology of pertussis. Other 
countries have considered administering booster doses 
to specific target groups such as new mothers, health 
care workers
30
 and adults (e.g. new parents) who are 
likely to have close contact with a non-immune or 
incompletely immune infant (<12months) (cocoon 
vaccination strategy).
10,31 
 
Conclusions 
The increasing reports of pertussis in Malta in 
2011 are of concern. A universal pertussis booster 
dose for adolescents and perhaps adults as well, is 
likely to reduce morbidity in adolescents and adults 
and protect susceptible infants through a reduction in 
transmission. Other specific groups, such as post-
partum mothers can alternatively or concomitantly be 
targeted prior being discharged from hospital. 
However, feasibility and cost-effective analyses are 
essential.  
 
A switch from the low dose diphtheria, tetanus 
and inactivated polio vaccine (dT-IPV which is 
administered at 16 yrs of age on the national 
immunisation schedule) to a similar combination 
vaccine that includes acellular pertussis (dTap-IPV) 
for adolescents and adults could be one simple 
measure. Other authors have recommended a regular 
dTaP booster vaccine every 10 years for adults; 
however this poses a substantial resource 
challenge.
10,30
 
There is also the need for introducing more 
sensitive laboratory methods, like molecular 
techniques, to improve the diagnosis of pertussis, 
however late notifications are likely to hinder this. In 
addition, doctors need to become more aware of the 
possibility of pertussis amongst adults and 
adolescents
13
 especially in individuals with a persistent 
cough.
10,11 
Early accurate diagnosis is necessary to control 
transmission of the disease
 
and enable prompt 
antibiotic treatment. The atypical presentations 
indicate that clinical diagnosis is not likely to be 
enough as it was in the pre-vaccination era and regular 
laboratory testing is essential.
10,11
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